Slide 1: Corporate Presentation
Corporate Presentation March 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 3: Company Overview
Company Overview • Focused on developing and commercializing DNA medicines to treat and protect people from HPV-related diseases, cancer, and infectious diseases • Biologics License Application (BLA) for lead program (INO-3107) accepted for review by FDA - Potential treatment for rare disease: Recur
Slide 4: Advancing a Diversified Clinical Pipeline
Advancing a Diversified Clinical Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION DMAbs INO-5401 VGX-3100 INO-3107 * Various Targets BRCA 1/2 Mutation Anal Dysplasia RRP DPROTs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer DLNPs INO-6172 INO-5412 Various targets HIV + c
Slide 5: DNA Medicine Platform
DNA Medicine Platform Harnessing the power of in vivo protein production
Slide 6: DNA Medicines: Customized In Vivo-Generated Proteins
DNA Medicines: Customized In Vivo-Generated Proteins TARGET BIOENGINEERING & PRECISELY PROPRIETARY MECHANISM OF ACTION SELECTION GENE SEQUENCING DESIGNED DEVICES PLASMIDS Skeletal Muscle Cell Selected gene Antigen-specific cytotoxic T cells to treat disease Binding/neutralizing antibodies and T cell
Slide 7: Key Features of our DNA Medicines Platform
Key Features of our DNA Medicines Platform Strengths include versatility & immunogenicity Induces antigen/protein-specific Well tolerated in nearly immune responses offering therapeutic 19,000 administrations and prophylactic protection (~6k clinical trial participants) Ability to be re-dosed Abilit
Slide 8: CELLECTRA Delivery Device Enhances Uptake of DNA Medicine
CELLECTRA® Delivery Device Enhances Uptake of DNA Medicine CELLECTRA 5PSP Track record of success in the clinic: • Intramuscular (IM) • Nearly 6,000 subjects & 19,000 injection • Delivers DNA doses given by both investigational/ plasmid contained in commercial-ready CELLECTRA devices cartridge • Uti
Slide 9: Focus on HPV-Related Diseases
Focus on HPV-Related Diseases
Slide 10: Human Papillomavirus: A Global Concern
Human Papillomavirus: A Global Concern • HPV is a group of viruses with approximately 200 types • Nearly everyone will become infected with some HPV type in their lifetime - The good news: ~90% of all infections clear naturally and don't result in disease - The bad news: persistent infection can lea
Slide 11: INOVIO's Development Experience Across HPV Spectrum
INOVIO’s Development Experience Across HPV Spectrum • Studies ranging from Phase 1 to Phase 3 • Involving patients with RRP, HSIL (cervical, anal & vulvar), head and neck cancers 12 trials, 900+ participants, 2000+ administrations in HPV-related diseases 11
Slide 12: Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis
Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) • BLA accepted by FDA for review under Accelerated Approval program • PDUFA target date of Oct. 30, 2026
Slide 13: INO-3107 for Recurrent Respiratory Papillomatosis
INO-3107 for Recurrent Respiratory Papillomatosis (RRP) RRP is a rare disease characterized by small, wart-like growths (papillomas) in the respiratory tract • Insufficient immune response that fails to prevent and clear HPV-6 and -11 infection leads to RRP Affects ~14,000 people in U.S., 1.8 per 10
Slide 14: Why every surgery matters to RRP patients
Why every surgery matters to RRP patients: “ The cumulative risk for injury increases with every surgery, but ultimately it only takes 1 surgical misadventure to permanently damage the larynx.” Factors Associated with Iatrogenic Laryngeal Injury in RRP Otolaryngology, 2024 Apr;170(4):1091-1098. doi:
Slide 15: Phase 1/2 Multi-Center Clinical Trial at 8 Clinical Sites
INO-3107 Phase 1/2 Multi-Center Clinical Trial at 8 Clinical Sites RRP-001 PHASE 1/2 OPEN-LABEL STUDY RRP-002 DURABILITY EXTENSION / FOLLOW-UP Baseline: DAY 0 52 WEEKS 104 WEEKS 156 WEEKS Patients Enrolled 4 Doses of INO-3107 Completed Study Consented to Follow Up Median Completed Follow Up Follow U
Slide 16: Statistically Significant Reduction in Surgeries
INO-3107 RRP-001 PHASE 1/2 TRIAL RESULTS Statistically Significant Reduction in Surgeries* Vast Majority of Patients Saw a Reduction in Surgery Data published in Nature Communications February 12, 20251 PARAMETERS CR Complete Response: no surgeries during a 52-week treatment phase PR Partial Respons
Slide 17: Reduction in Surgeries Continued to Improve After Year 1
INO-3107 Reduction in Surgeries Continued to Improve After Year 1 ORR was 72% at Week 52, improving to 86% by Week 104 for second twelve-month period The pre-treatment mean for surgeries in the year prior to start of INO-3107 was 4.1 (range 2-8) vs. 1.7 in Year 1 and 0.9 in Year 2 INO-3107 CLINICAL
Slide 18: Over 75% Fewer Surgeries 2 Years After Treatment
INO-3107 Over 75% Fewer Surgeries 2 Years After Initial Treatment Regimen* MEAN SURGERIES PER YEAR PRE-TREATMENT WeekYEAR -52 to-10(N=32) (N=32) 4.1 WeekYEAR 1 (N=32) 52 Visit (N=32) 1.7 Longer-term therapy could offer POST-TREATMENT YEAR104 Week 2 (N=28) (N=28) 0.9 potential for maintenance and ext
Slide 19: Immunology Data Correlates with Clinical Response
INO-3107 Immunology Data Correlates with Clinical Response PRIOR TO INO-3107 Right kind of immune responses generated to fight HPV in all 32 patients (antigen specific cytotoxic T cell response) T cells observed to infiltrate the papilloma/airway tissue Created an anti-viral immune response in papil
Slide 20: Proposed Mechanism of Action
INO-3107 Proposed CIRCULATION Mechanism Expansion of pre-existing T Pre-existing of Action T cells in blood cells and Induction of novel Treatment with T cells in blood • Induce HPV INO-3107 antigen-specific Low T cell Immunotherapy Mass trafficking by T cell responses trafficking INO-3107 induced T
Slide 21: Surgery Should Be a Last Resort, Not a First-line Treatment
INO-3107 Surgery Should Be a Last Resort, Not a First-line Treatment INO-3107: RRP-001 PHASE 1/2 OPEN-LABEL STUDY AT 8 SITES PATIENTS WITH 2+ SURGERIES IN YR PRIOR TO TREATMENT Baseline: DAY 0 WEEK 52 - Initial Surgery: up to 14 days before first dose Patients Enrolled 4 Doses of INO-3107 Completed
Slide 22: Accelerated Approval: We Believe INO-3107 Meets FDA Criteria
INO-3107 Accelerated Approval: We Believe INO-3107 Meets FDA Criteria* Meaningful therapeutic benefit Potential to meet remaining over existing treatments critical unmet need EFFICACY SAFETY DIFFERENTIATED MOA • 50% - 100% reduction • No required minimal residual • Ability to treat patients in surge
Slide 23: Market Research Continues to Support Preferred Product Profile
INO-3107 Market Research Continues to Support Preferred Product Profile EFFICACY TOLERABILITY SIMPLICITY Improving response over time Well tolerated Patient-centric treatment • Overall Response Rate (50% to • 41% (13/32) reported treatment- • Office-based administration that 100% reduction in surger
Slide 24: Advancing Launch Preparations
INO-3107 Advancing Launch Preparations Key Market Research and Planning: 300-400 laryngologists • Continued critical research with payers treat the majority of RRP patients and completed research supporting a positively differentiated product profile • Developed pricing strategy with price optimizat
Slide 25: Late-Stage Pipeline Candidates
Late-Stage Pipeline Candidates Designed to address high unmet needs, multiple near- and mid-term catalysts
Slide 26: Opportunity to Impact HPV-Related Throat Cancer
INO-3112 +LOQTORZI Opportunity to Impact HPV-Related Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma (Throat Cancer) • Throat cancer: high unmet need in fast-growing indication - Surpassed cervical cancer as most common HPV-related cancer diagnosed in the U.S. (~ 20,000 new cases/yr) -
Slide 27: Innovative DNA Immunotherapy for Glioblastoma
INO-5412 +cadonilimab Innovative DNA Immunotherapy for Glioblastoma (GBM) • GBM: most common and aggressive form of brain cancer, desperate need for new treatments - ~ 15,000 people diagnosed with GBM each year glioblastoma - Poor prognosis, with a typical life expectancy of 15 to 18 months and a 5-
Slide 28: INO-5401 + INO-9012 for Newly Diagnosed GBM
INO-5401 INO-5401 + INO-9012 for Newly Diagnosed GBM Completed Phase 1/2 Combination Trial with LIBTAYO® • INO-5401 + INO-9012 with LIBTAYO and 40 Gy radiation/TMZ were observed to have favorable tolerability and immunogenicity - INO-5401 is a DNA medicine composed of plasmids that encode for 3 tumo
Slide 29: Boosts Binding & Neutralizing Antibodies Against Ebola
INO-4201 EBOLA BOOSTER VACCINE CANDIDATE Boosts Binding & Neutralizing Antibodies Against Ebola Recent progress: • Re-submitted Ph 2 trial design to FDA BINDING ANTIBODIES NEUTRALIZING ANTIBODIES • Preparing to submit Phase 1b trial data to peer-reviewed journal with collaborators • New FANG assay d
Slide 30: Completed Phase 2 Trial in HIV-Negative Participants
VGX-3100 ANAL HSIL Completed Phase 2 Trial in HIV-Negative Participants Precancerous 3 or 4 dose regimen Phase 2 Anal Dysplasia: open-label trial N=24 at Months 0, 1, 3 and Week 36 (optional) Final findings Clearance of HPV-16/18+ lesions: The Spontaneous Rate (6 months after start of treatment) 50%
Slide 31: Ongoing Phase 2 Trial in HIV-Positive Participants
VGX-3100 ANAL HSIL Ongoing Phase 2 Trial in HIV-Positive Participants • Trial initiated in September 2018 • 80-participant, open-label Phase 2 trial • 4 doses at week 0, 4, 12, and 24 Final findings (6 months after start of treatment) • Primary endpoint: overall response rate at 48 weeks – defined a
Slide 32: The Next Generation of DNA Medicine
DMAbTM DNA ENCODED MONOCLONAL ANTIBODIES The Next Generation of DNA Medicine MYOCYTE DMAb technology enables in vivo production of monoclonal antibodies (mAbs) • DNA is administered via CELLECTRA device to enable local expression of the genes coding for the antibodies in the deltoid muscle. • DMAbs
Slide 33: Ongoing Phase Trial: Data Published in Nature Medicine
DMAbTM Ongoing Phase 1 Trial: Data Published in Nature Medicine • Long-lasting in vivo antibody production: DMAb levels remained stable for 96 weeks in all participants DURABLE AND CONSISTENT DMAb EXPRESSION reaching that timepoint 2048 Serum Concentration, ng/mL 1024 1 x 0.5 mg • No anti-drug antib
Slide 34: Potential to Address Challenges of Conventional mAbs
DMAbTM Potential to Address Challenges of Conventional mAbs Challenges with mAbs1 INOVIO’s DMAb technology • Stability: susceptible to a variety of chemically- • Rapid manufacturing, low cost of production, and and temperature-induced structural changes temperature-stable storage and distribution •
Slide 35: Potential Shown in Multiple Disease Models
DMAbTM Potential Shown in Multiple Disease Models • Delivery of anti PCSK-9 in mice lowers LDL PCSK-9 Influenza A & B • Broadly neutralizing pan-influenza A & B approach cholesterol (Khoshnejad et al Mol Ther 2018) • Delivery of multiple antibodies (Elliott et al NJV 2017) viruses • Demonstrated dis
Slide 36: Potential as a New Treatment Paradigm in Rare Diseases
DPROT DNA ENCODED PROTEINS Potential as a New Treatment Paradigm in Rare Diseases • Builds on DMAb technology: targets long-term complex protein expression with ability to re-dose due to lack of anti-vector Factor VIII Protein Structure immunity • AimsFinal to address findingsshortcomings of convent
Slide 37: INOVIO Pipeline
INOVIO Pipeline PRODUCT INDICATION PHASE SPONSOR FUNDERS/COLLABORATORS VGX-3100 Cervical Dysplasia (HSIL) – China 3 VGX-3100 Anal Dysplasia (HSIL) – HIV+ 1 INO-5401 Glioblastoma 1/2 INO-5412 Glioblastoma 2 INO-5401 BRCA 1/2 Mutation 1 INO-4800 COVID-19 (Solidarity) 3 INO-6172 HIV 1 INO-6160 HIV 1 DM
Slide 38: Progressing Strategy to Unlock the Promise of DNA Medicine
Progressing Strategy to Unlock the Promise of DNA Medicine NEAR TERM MID TERM NEXTGEN Working to Deliver Advancing Diversified Innovating NextGen INO-3107 to Patients Clinical Pipeline DNA Medicines • BLA accepted for review under accelerated • Additional clinical candidate partnerships, • DMAbs: ap
Slide 39: Thank you
Thank you Investors: Peter Vozzo Peter.Vozzo@icrhealthcare.com Media: Jennie Willson Jennie.Willson@inovio.com